Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma

INTRODUCTION: Panobinostat, bortezomib, and dexamethasone combination therapy demonstrated progression-free survival (PFS) benefit over bortezomib and dexamethasone alone in the PANORAMA-1 study in relapsed/refractory multiple myeloma (MM). Here, we present data from a phase II study (NCT02290431) o...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Acta Haematol
Huvudupphovsmän: Suzuki, Kenshi, Sunami, Kazutaka, Matsumoto, Morio, Maki, Akio, Shimada, Fumika, Suzuki, Kazuyuki, Shimizu, Kazuyuki
Materialtyp: Artigo
Språk:Inglês
Publicerad: S. Karger AG 2021
Ämnen:
Original Paper
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC8259066/
https://ncbi.nlm.nih.gov/pubmed/33279887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000508529
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk